Keio Multicenter Trial in High-dose Interferon-α2b Treatment for Chronic Hepatitis C

この論文にアクセスする

この論文をさがす

著者

抄録

The efficacy of two different high-dose treatment of IFN-α2b was evaluated in this study. Serum hepatitis C virus (HCV) RNA levels were semi-quantified by simplified reverse transcription-polymerase chain reaction. Seventy-one patients with chronic hepatitis C received 10 million units of IFN-α2b daily for 2 weeks or trice a week for 24 weeks. Alanine aminotransferase (ALT) levels overall normalized in 78.1% and 51.6% of the cases at the end of the therapy and 6 months after that, respectively. HCV RNA disappeared in 71.9% and 35.7% of the patients at the end of the therapy and 6 months after that, respectively. There was no significant difference between the 2 different regimes. The efficacy of the treatment was fair in cases in which the pretreatment level of the viral amount was low. The results of this study indicate that daily administration of IFN in the first 2 weeks during 6-month course does not increase the efficacy of the therapy in such a high-dose treatment regime.

収録刊行物

  • Keio journal of medicine  

    Keio journal of medicine 45(3), 161-167, 1996-09-01 

    The Keio Journal of Medicine

参考文献:  26件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

被引用文献:  5件

被引用文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

各種コード

  • NII論文ID(NAID)
    10021986286
  • NII書誌ID(NCID)
    AA00710216
  • 本文言語コード
    ENG
  • 資料種別
    ART
  • ISSN
    00229717
  • データ提供元
    CJP書誌  CJP引用  J-STAGE 
ページトップへ